Ticlopidine contraindications: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Contraindications== | ==Contraindications== | ||
The use of ticlopidine hydrochloride is contraindicated in the following conditions: | The use of ticlopidine hydrochloride is contraindicated in the following conditions<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TICLOPIDINE HYDROCHLORIDE TABLET, FILM COATED [APOTEX CORP.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=707127cb-cdcd-81b0-274d-3c11fefa6824 | publisher = | date = | accessdate =}}</ref>: | ||
:*'''[[Hypersensitivity]]''' to the drug | :*'''[[Hypersensitivity]]''' to the drug. | ||
:*Presence of '''hematopoietic disorders''' such as [[neutropenia]] and [[thrombocytopenia]] or a past history of either [[TTP]] or [[aplastic anemia]] | :*Presence of '''hematopoietic disorders''' such as [[neutropenia]] and [[thrombocytopenia]] or a past history of either [[TTP]] or [[aplastic anemia]]. | ||
:*Presence of a '''hemostatic disorder''' or active pathological bleeding (such as bleeding [[peptic ulcer]] or [[intracranial bleeding]]) | :*Presence of a '''hemostatic disorder''' or active pathological bleeding (such as bleeding [[peptic ulcer]] or [[intracranial bleeding]]). | ||
:*Patients with '''severe [[Hepatic failure|liver impairment]]'''. | :*Patients with '''severe [[Hepatic failure|liver impairment]]'''. | ||
==References== | ==References== | ||
Revision as of 00:44, 6 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
The use of ticlopidine hydrochloride is contraindicated in the following conditions[1]:
- Hypersensitivity to the drug.
- Presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either TTP or aplastic anemia.
- Presence of a hemostatic disorder or active pathological bleeding (such as bleeding peptic ulcer or intracranial bleeding).
- Patients with severe liver impairment.
References
Adapted from the FDA Package Insert.